Abstract-Since the discovery of nonpeptidic ligands, the receptors for angiotensin (Ang) II have been classified into 2 subtypes (Ang II type 1 receptor [AT 1 -R] and Ang II type 2 receptor [AT 2 -R]). AT 1 -R mediates most of the cardiovascular actions of Ang II. AT 2 -R is expressed at very high levels in the developing fetus. Its expression is very low in the cardiovascular system of the adult. The expression of AT 2 -R can be modulated by pathological states associated with tissue remodeling or inflammation. In failing hearts or neointima formation after vascular injury, AT 2 -R is reexpressed in cells proliferating in interstitial regions or neointima and exerts an inhibitory effect on Ang II-induced mitogen signals or synthesis of extracellular matrix proteins, resulting in attenuation of the tissue remodeling. An extreme form of cell growth inhibition ends in programmed cell death, and this process, which is initiated by the withdrawal of growth factors, is also enhanced by AT 2 -R. Cardiac myocyte-or vascular smooth muscle-specific mice that overexpress AT 2 -R display an inhibition of Ang II-induced chronotropic or pressor actions, suggesting the role of AT 2 -R on the activity of cardiac pacemaker cells and the maintenance of vascular resistance. AT 2 -R also activates the kinin/nitric oxide/cGMP system in the cardiovascular and renal systems, resulting in AT 2 -R-mediated cardioprotection, vasodilation, and pressure natriuresis. These effects, transmitted by AT 2 -R, are mainly exerted by stimulation of protein tyrosine or serine/threonine phosphatases in a Gi protein-dependent manner. The expression level of AT 2 -R is much higher in human hearts than in rodent hearts, and the AT 2 -R-mediated actions are likely enhanced, especially by clinical application of AT 1 -R antagonists. Thus, in this review, the regulation of AT 2 -R expression, its cellular localization, its pathological role in cardiovascular and kidney diseases, and pharmacotherapeutic effects of AT 2 -R stimulation are discussed. (Circ Res. 1998;83:1182-1191.)
T he biological effects caused by circulating angiotensin (Ang) II are diverse, widespread, and play a critical role in the regulation of the cardiovascular and renal systems ( Figure 1 ). The components of the renin-angiotensin system are present in peripheral tissues such as vasculature, kidneys, adrenal glands, and hearts, all of which locally produce Ang II. 1 Ang II produced in the peripheral tissues binds to specific receptors through the autocrine or paracrine system and exerts growth-promoting effects on the tissue remodeling process. 2 The well-known Ang II actions such as the regulation of blood pressure and water-electrolyte balance have been attributed mainly to the activation of various signaltransduction pathways modulated by Ang II type 1 receptor (AT 1 -R). However, the discovery of highly selective, peptidic, and nonpeptidic ligands such as CGP42112A and PD123319 has led to the identification of a second subtype (Ang II type 2 receptor [AT 2 -R]. [3] [4] [5] [6] [7] This receptor is expressed at very high levels in the developing fetus. By contrast, in the adult, its expression is restricted to the adrenals, uterus, ovary, heart, and specialized nuclei in the brain. Initially, the cDNA for AT 2 -R was isolated by expression cloning from PC12 cells 8 and whole fetus. 9 Knockout mice for the AT 2 -R gene were developed, and studies of these mice suggested that AT 2 -R has a physiological role in blood pressure control and emotional instability and fearfulness. 10, 11 In addition, an AT 2 -R-mediated inhibitory effect on the growth-promoting signals has been found. 5, 6 Treatment with AT 1 -R antagonists causes a marked elevation of levels of plasma Ang II, which selectively binds to AT 2 -R and exerts as yet undefined effects. 12 Thus, elucidation and understanding of AT 2 -Rmediated pathological actions have important pharmacotherapeutic implications. This review examines the results of studies into the structure-function, transcriptional control and gene expression, signal-transduction mechanism, cellular distribution, and pathophysiological roles of AT 2 -R as well as potential issues concerning clinical application of AT 1 -R antagonists.
Structural Features of AT 2 -R
The second isoform of the Ang II receptor, AT 2 -R, has been defined as the receptor that binds specifically to CGP42112 and to a series of PD compounds. 4 Its abundance in mesenchymal tissues of the developing fetus, such as the uterus, the adrenal medulla, pheochromocytoma, and specific brain regions suggested neuronal and developmental roles for AT 2 -R. [3] [4] [5] [6] [7] 13, 14 This receptor had been thought not to be a seven-transmembrane receptor, given that its ligand binding affinity was not reduced by stable GTP analogues, and it did not show agonist-induced internalization. 3 , 5 The cDNA isolated from PC12 cells8 or rat fetus 9 by expression cloning encoded a protein with a 363 amino-acid residue, which corresponded to a theoretical molecular weight of 41 303, and it showed a seven-transmembrane domain receptor that included the highly conserved sequence Asp141-Arg142-Tyr143 in the N-terminal region of the second cytosolic loop and the conservation of residues known to be crucial for binding in other G protein-coupled receptors. However, it shared only a 32% amino-acid sequence identity with AT 1a -R. Mutational analysis of AT 1a -R indicated that the Tyr108 in extracellular loop 1, the Arg1082 in extracellular loop, and the Asp297 in extracellular loop 3 play an important role in Ang II binding to AT 1a -R, whereas mutations of Arg182 and Asp297, but not Tyr108, drastically impaired Ang II binding to AT 2 -R. 15 The AT 2 -R gene has been characterized in both the mouse 16, 17 and human. 18 -20 It exists as a single copy localized on the X chromosome in both species and contains no intron in its coding region. This excludes the possibility of multiple forms of AT 2 -R encoded by several homologous genes or delivered by alternative splicing. Genomic Southern blot analyses also have indicated that there are no other subtypes to the AT 2 -R gene family, such as AT 1a -R or AT 1b -R, found in the AT 1 -R family. 8, 9 Regulation of AT 2 -R Gene Transcription and Expression
The gene expression of AT 2 -R is regulated by multiple factors (Table  1) . Increase in intracellular CA 2ϩ levels by Ca 2ϩ ionophore and activation of protein kinase C (PKC) by phorbol ester markedly downregulated the AT 2 -R mRNA level in PC12 cells. 21 Norepinephrine and Ang II (via AT 1 -R), which elevate Ca 2ϩ levels and activate PKC, downregulate the AT 2 -R expression in cardiac myocytes. 22 Growth factors (epidermal growth factor, nerve growth factor, and platelet-derived growth factor) also downregulate AT 2 -R expression in PC12 cells, 22, 23 R3T3 cells, 24, 25 and vascular smooth muscle cells (VSMCs). 26 Stimulation of growth factor receptors results in the formation of an activator protein AP-1 complex including Fos and Jun transcription factors, which in turn binds to the AP-1 site of the promoter region of many genes. This effect is mimicked by PKC activation with phorbol ester. Considering that both growth factors and phorbol ester suppress the AT 2 -R mRNA expression, their effects may converge on the AP-1 site. In agreement with this hypothesis, the AP-1 site was shown to be present in the promoter region of rat AT 2 -R, 23 and AT 2 -R gene transcription assessed by nuclear runoff assays is inhibited by growth factors and phorbol ester. 22 The promoter region of the AT 2 -R gene possesses a glucocorticoid response element, CAAT/enhancer-binding protein, nuclear factor-interleukin 6, AP-1, and a cAMP response element, suggesting a transcriptional regulation by glucocorticoids, cytokines, phorbol esters, and cAMP. 23, 27 Interestingly, the inhibition of AT 2 -R expression by glucocorticoid or cAMP analogues is regulated at the gene transcription level. 22 Downregulation by glucocorticoids, growth factors, phorbol ester, Ca 2ϩ ionophore, Gq-coupled receptor stimulation Upregulation by insulin, insulin-like growth factor, cytokines, interstitial region in remodeling heart the upregulation of the AT 2 -R gene by interleukin (IL)-1␤, insulin, and insulin-like growth factors in R3T3 cells and VSMCs. IL-1␤ is one of the important cytokines mediating inflammation, and it may be involved in AT 2 -R induction during the process of inflammation. 30 Fetal mesenchymal fibroblasts, which highly express AT 2 -R, express a substantial amount of insulin-like growth factor-I and its receptor 31 ; insulin may be important for the abundant expression of AT 2 -R in fetal mesenchymal tissues. Although these multiple factors regulate the expression of AT 2 -R, the molecular mechanisms responsible for hormonal control and cell-specific expression of the AT 2 -R gene are less defined than those for control and expression of the AT 1a -R gene. [32] [33] [34] [35] Expression of the AT 2 -R gene is dependent on growth state. When PC12 cells, 22 R3T3 cells, 36, 37 or mesangial cells 38 reach a confluent quiescent state, AT 2 -R expression is increased markedly. This gene regulation is exerted at the transcriptional level. 22, 23 Horiuchi et al 36, 37 demonstrated that interferon regulatory factor-1, the expression of which is increased during confluent state and by serum depletion, binds to the interferon regulatory factory-binding motif of the AT 2 -R gene promoter region and upregulates its gene transcription. 
Involvement of Phosphotyrosine Phosphatase
In contrast with AT 1 -R, the AT 2 -R-mediated signaling mechanism is not well established. Before the structure of AT 2 -R had been determined, numerous studies attempted to elucidate signal transduction pathways associated with this subtype. Cell lines such as PC12W cells, neuroblastoma (NG108-15, NIE-115), or fibroblasts (R3T3) expressing only AT 2 -R were used as models for signaling studies. In the PC12W and NIE-115 cells, AT 2 -R activates phosphotyrosine phosphatase (PTP) to inhibit cell proliferation 39, 40 and differentiation. 41 In NIH3T3 cells stably expressing AT 2 -R, Ozawa et al 42 also found the AT 2 -R-mediated inhibitory effect on serumstimulated cell growth in a pertussis toxin-sensitive manner. Using a membrane-associated fraction in the postnuclear fraction isolated form R3T3 cells, Tsuzuki et al 43, 44 reported that AT 2 -R stimulation caused activation of PTP when both nitrophenylphosphate and the peptide substrate Raytide containing a phosphotyrosine residue were used as targets. They also described the suppression of growth stimulation of R3T3 fibroblasts by basic fibroblast growth factor. This suppression correlated dose-dependently with AT 2 -R-mediated signals, suggesting the role of PTP in AT 2 -R-mediated inhibition of cellular growth. 43 
Inhibition of AT 1 -R-Mediated Extracellular Signal-Regulated Kinase Activation
In cells expressing AT 1 -R, Ang II activates extracellular signalregulated kinase (ERK), which leads to a mitogenic or hypertrophic response through activation of tyrosine kinase system. 45, 46 With use of coronary endothelial cells expressing both AT 1 -R and AT 2 -R 47 or an overexpression model of AT 2 -R in VSMC, 48 AT 2 -R was shown to have an inhibitory effect on AT 1 -R-mediated growth-promoting action assessed by DNA synthesis, and in the latter experiment, AT 2 -R decreased the AT 1 -R-mediated ERK activity. Janiak et al 49 reported the selective activation of AT 2 -R as an effective approach for the suppression of neointima formation after balloon catheterization. AT 2 -R stimulation inhibits AT 1 -R-mediated DNA and cell growth in myocytes 50 or fibroblasts 51, 52 isolated from neonatal rat hearts and in cardiac fibroblasts from myopathic hamsters. 52 The inhibition of DNA synthesis by AT 2 -R was also reported in zona glomerulosa cells from rat adrenal glands. 53 Furthermore, Masaki et al 54 ascertained that AT 2 -R significantly inhibits AT 1 -R-mediated ERK activation in perfused mouse hearts overexpressing AT 2 -R. The AT 2 -R-mediated antiproliferative effect on DNA synthesis also was demonstrated in embryonic renomedullary interstitial cells. 55 The mechanism of AT 2 -R participation in this process might be associated with reduced ERK activity caused by the activation of ERK phosphatase 1 (MKP-1), a dual-specificity phosphatase that acts on both phosphotyrosine and phosphothreonine. Horiuchi et al 56 reported that AT 2 -R stimulation dephosphorylates Bcl-2 by activating MKP-1 and induces apoptosis in PC12W cells. Bedecs et al 57 reported that AT 2 -R-mediated inhibition of serum-or growth factorinduced ERK activity in NIE-115 cells is associated with vanadatesensitive PTP, in which catalytic activity of Src homology 2 domain phosphatase-1 (SHP-1), a soluble PTP, is an early transducer of the AT 2 -R signaling pathway. These investigators also found that expression of MKP-1 is not modified by AT 2 -R. 57 In neuronal cultures isolated from neonatal rat hypothalamus or in nondifferentiated NG108-15 cells (neuroblastoma cells), activation of AT 2 -R reportedly elicits stimulation of outward 58, 59 and delayed rectifier K ϩ currents 60 and inhibits T-type Ca 2ϩ current. 61 These effects in neuronal cultures appear to be due to activation of serine/threonine phosphatase mediated in a Gi protein-dependent manner. In contrast, in neuroblastoma (NIE-115) AT 2 -R reportedly induces a marked decrease in phosphorylation of several cellular proteins on tyrosine residues. 62 Bottari et al 63 and Brechler et al 64 reported that AT 2 -R stimulation causes activation of a membrane-associated PTP and inhibition of atrial natriuretic peptide-sensitive particular guanylate cyclase via a G protein-independent pathway. These studies show that AT 2 -R inactivates ERK and that ERK activity can be used as a sensitive index of AT 2 -R action, rather than used to directly determine PTP activity, which is difficult because of the high background contribution of several PTPs. 5
AT 2 -R-Mediated Induction of Apoptosis
An extreme way of cell growth inhibition might direct cells into programmed cell death. AT 2 -R has been associated with apoptotic changes in rat ovarian granulosa cells in culture. 65 Prolonged serum depletion, which is enhanced by Ang II treatment, elicits programmed cell death of R3T3 cells. 66 PC12W cells also undergo apoptosis upon depletion of nerve growth factor, which also is enhanced by Ang II, and this effect was attenuated by inhibition of MKP-1 function and by the PTP inhibitor orthovanadate. 66 Horiuchi et al 56 reported that ERK plays a critical role in inhibiting apoptosis in PC12W cells by phosphorylating Bcl-2 and that AT 2 -R inhibits ERK activation, resulting in the inactivation of Bcl-2 and the induction of apoptosis. Hayashida et al 67 showed that a synthetic peptide containing a 22-residue sequence from the third cytosolic loop of rat AT 2 -R suppresses the ERK activity when transferred into VSMCs, and that this inhibition is reversed by pertussis toxin or orthovanadate, suggesting that the third cytosolic loop of AT 2 -R plays a role in the activation of a Gi-mediated PTP that inhibits ERK. Zhang and Pratt 68 also reported the direct binding of AT 2 -R to immunoprecipitated Gi ␣2 and Gi ␣3 proteins. In contrast, Cigola et al 69 reported that the stimulation of AT 1 -R but not AT 2 -R induces apoptosis by Ca 2ϩ -dependent endonuclease in neonatal rat myocytes. No apoptotic changes were observed in cardiac myocytes from transgenic mice expressing AT 2 -R specifically in the heart. 54 Involvement of Bradykinin/Nitric Oxide/cGMP Systems AT 2 -R-mediated activation of the kinin and nitric oxide (NO) system has been reported in bovine endothelial cells, 70 isolated rat carotid arteries, 71 canine microvessels from coronary arteries, 72 rat aortic strips, 73 rat kidney, 74 and rat heart. 75 In a rat model of heart failure due to myocardial infarction, 75 the reduced cardiac function and cardiac fibrosis were improved by an AT 2 -R antagonist as well as by a bradykinin receptor antagonist. In stroke-prone spontaneously hypertensive rats, 76 aortic cGMP production stimulated by Ang II infusion was inhibited by an AT 2 -R antagonist as well as by a bradykinin receptor antagonist or NO synthase inhibitor, suggesting the involvement of bradykinin and NO in the AT 2 -R signaling. Siragy et al 74 reported using a microdialysis technique that AT 2 -R stimulates renal production of cGMP in response to Na depletion, and that this effect is mediated by NO production. 77 AT 2 -R-mediated NO production also is involved vitally in AT 2 -R-mediated pressure natriuresis an diuresis. 78, 79 
Expression and Cellular Localization of AT 2 -R in the Heart
Inhibition of Ang II production by angiotensin-converting enzyme (ACE) inhibitors is a major new approach for treatment of hypertension, cardiovascular remodeling, heart failure, and chronic renal diseases. Both AT 1 -R and AT 2 -R have been observed in cardiac myocytes isolated from neonatal rat hearts. 50, 80, 81 Cardiac fibroblasts isolated from neonatal and adult rat hearts express abundant amounts of AT 1 -R (Ϸ8-fold more than that in myocytes) 80 but not of AT 2 -R. [81] [82] [83] [84] Although some attempts to detect the AT 2 -R in adult rodent myocytes by a binding assay or polymerase chain reaction have proved negative, 84 -86 other researchers have obtained positive results. 24, [87] [88] [89] [90] Although autoradiography results also indicated the presence of AT 2 -R protein in the adult rat myocardium, 91 an in situ hybridization study did not detect AT 2 -R mRNA in cardiac muscle of adult rat but did show it in the annulus of all valves during the perinatal period. 92 Thus, the proportion of cardiac AT 2 -R expressed in situ in the rat heart varies from that detected in cultured cells, 93 possibly reflecting downregulation of AT 2 -R expression after the isolation of mammalian cells 84, 94 and the growth-dependent regulation of AT 2 -R expression in cultured cells. 21, 66 The expression pattern of AT 2 -R in the human heart is quite different from that in the rat heart, and human adult hearts express substantial amounts of AT 2 -R. Tsutsumi et al 95 found that the amount of Ang II receptors in human left ventricular tissues was in the range of 3.8 to 17.3 fmol/mg protein, and that the proportion of AT 2 -R to the total Ang II binding sites was about 41%. The amount of Ang II receptors is similar to the amounts reported by others 96 -100 ; however, the proportion of AT 2 -R to binding sites differs between these studies. Interestingly, Tsutsumi et al 95 found that AT 1 -R and AT 2 -R decreased by as much as by 30Ϯ2.7% and 8.2Ϯ1.4%, respectively, during the freezing of tissue samples. This finding means that great care should be taken to factor in the experimental conditions when Ang II receptor densities are measured in tissue samples. In addition, Rogg et al 101 reported a relatively high amount of Ang II receptors (118 fmol/mg protein) in the human atria when they used combined fractions including plasma membranes and internalized receptors; other investigators 96 -100 measured Ang II receptors using only membrane fractions. In fact, Regitz-Zagrosek et al 97 found that the Ang II receptor densities determined with combined fractions were increased markedly compared with those found by using only membranes. Urata et al 96 reported that the basal portion of human left ventricular tissues contained higher densities of Ang II receptors than those in other portions. Ang II receptor densities are affected by the methodological differences, such as dissimilarities in the purity of membrane fractions, the portion of ventricles examined, or membrane preparation.
Cellular localization of AT 2 -R in the human heart has been examined mainly using emulsion autoradiography. 95, 99, 102, 103 The expression of cardiac AT 2 -R was localized more highly in the fibroblasts present in the interstitial regions than those in the myocardium 95, 99, 102 (Figure 2 ). In contrast, AT 1 -R is localized most abundantly in nerves distributed in the myocardium, and its expression level in the myocardium itself or interstitial regions is very low, 95, 99, 102 although the AT 1 -R protein might be partially degraded during sample preparation such as during the freezing of tissues. 95 These findings imply that the expression of AT 2 -R in the heart increases in parallel with the progression of interstitial fibrosis, which corresponds to the reports that AT 2 -R expression in human hearts increases during cardiac remodeling as a result of dilated cardiomyopathy or ischemic heart diseases. 95, 99, 102 AT 2 -R expression in human hearts also reportedly increases in parallel with intracardiac filling pressures. 103 The results of ligand binding and autoradiographic studies on human heart tissues appear to differ from those obtained in studies of isolated cardiac cells. Although AT 2 -R binding sites are localized in interstitial regions in human hearts in situ, 95, 99, 102 cultured human cardiac fibroblasts display mainly AT 1 -Rmediated effects on collagen synthesis. 104 Atypical Ang II binding sites for Ang 1-7 were detected on human cardiac fibroblasts, 105, 106 whereas Ang 3-8 binding sites were present on rabbit cardiac fibroblasts 107 or myocardial membranes of guinea pig and rabbit hearts. 108 Two subtypes of the AT 1 -R, AT 1a -R and AT 1b -R, were encoded in human tissues, 109 and there was heterogeneity in mammalian AT 2 -R, 110 but these reports are isolated ones, which are not followed up by confirmation.
Regulation of Cardiac AT 2 -R Expression During Cardiac Remodeling
Both AT 1 -R and AT 2 -R are upregulated to different extents in pathological conditions, such as cardiac hypertrophy, 87,111-113 an 52, 114 and in mechanical stretch-induced hypertrophy of myocytes, 81 whereas in failing human hearts the proportion of AT 2 -R to AT 1 -R is relatively increased by AT 1 -R downregulation. 95, 97, 98, 101, 103, 115 The expression profiles of AT 1 -R and AT 2 -R during cardiac remodeling are summarized in Table 2 . In hereditary myopathic hamsters, cardiac AT 1 -R increases in the hypertrophic state but is downregulated in parallel with progressive heart failure, whereas the expression of AT 2 -R increases during the heart failure stage rather than during the hypertrophic state. 52 In the aortic banding model of rats, Lopez et al 112 reported that the proportion of AT 2 -R increases because of downregulation of AT 1 -R. Emulsion autoradiography showed that AT 1 -R is present mainly in the myocardium of normal human hearts in situ and that its expression level is downregulated during progressive heart failure. 95 Recent human studies showed that the expression of AT 1 -R is downregulated in failing hearts 95, 97, 98, 101, 103, 115 and, conversely, that AT 2 -R is increased in the interstitial regions. 99, 102 The mechanism by which AT 2 -R expression is increased in cardiac fibroblasts remains unknown. Ichiki et al 24 and Kambayashi et al 26 reported the upregulation of the AT 2 -R gene by IL-1␤, insulin, and insulin-like growth factors in R3T3 cells, and VSMCs. IL-1␤ is one of the important cytokines mediating inflammation and may be involved in AT 2 -R induction during the process of inflammation associated with cardiac remodeling, as observed in experimental wound healing. 116 Given that most cells that abundantly express AT 2 -R in fetal mesenchymal tissues are undifferentiated fibroblasts, 117 similar cells may be induced in the interstitial regions. Fetal mesenchymal fibroblasts, which highly express AT 2 -R, express a substantial amount of insulin-like growth factor-I and its receptor. 118 Insulin and insulinlike growth factors might also be important for the abundant expression of AT 2 -R in fibroblasts proliferating in fibrous regions.
Pathophysiological Role of AT 2 -R in Remodeling of the Heart
The dominant expression of AT 2 -R in cardiac fibroblasts has interesting pharmacological implications for the predicted actions of AT 1 -R antagonists. Because circulating Ang II levels are increased by administration of AT1-R antagonists 11 and because Ang II preferentially binds to cardiac AT 2 -R, AT 2 -R-mediated actions are expected to be activated in failing hearts, especially in cardiac fibroblasts. Using fibroblasts from myopathic hamster hearts, Ohkubo et al 52 determined that AT 2 -R has an inhibitory effect on AT 1 -R-mediated synthesis of DNA and extracellular collagenous protein, such as fibronectin and collagen type 1, and that AT 2 -R stimulation inhibits the progression of interstitial fibrosis in myopathic lesions. Several other studies also demonstrated an antigrowth role of AT 2 -R in the cardiovascular system, shown by its inhibition of the proliferation of rat coronary endothelial cells 47 and transfected VSMCs, its modulation of arterial hypertrophy, and fibrosis in Ang II-induced hypertensive rats, 119 and its prevention of Ang II-induced growth of cultured neonatal rat myocytes. 50 AT 2 -R-mediated apoptosis might be one mechanism by which AT 2 -R induces an antigrowth effect. 63, 64 Indeed, apoptotic myocytes have been found to occur relatively frequently in the border zone of infarcted human heart tissues, 120 and researchers have speculated that AT 2 -R may affect changes in myocardial structure by mediating apoptosis. 121 Liu et al 75 reported that the cardioprotective action of AT 1 -R antagonists is mainly exerted by the selective stimulation of AT 2 -R, which is mediated partly by the kinin/NO system. Ang II-induced cardiac fibrosis is increased by chronic inhibition of NO synthase, 122 and generation of coronary kinin mediates NO release after Ang II receptor stimulation. 123 ATR2-R-mediated activation of the kinin/NO system also is involved in pressure natriuresis and diuresis of the kidneys. 78, 79 The AT 2 -R in cardiac myocytes may have an additional action distinct from the effect in cardiac fibroblasts. In mice developed for cardiomyocyte-specific overexpression of AT 2 -R, with use of an ␣-myosin heavy chain promoter, Ang II-induced positive chronotropic action is inhibited (Figure 3) . 54 In myocytes from neonatal rat hearts expressing both AT 1 -R and AT 2 -R, Booz et al 50 found that AT 2 -R stimulation inhibits Ang II-induced myocyte hypertrophy by decreasing the protein-to-DNA ratio and increasing protein degradation. Kijima et al 81 reported that AT 2 -R in hypertrophic myocytes at least partially exerts an inhibitory effect on AT 1 -R-mediated positive chronotropic or hypertrophic actions by showing upregulation of AT 2 -R in stretch-induced myocyte hypertrophy.
Cellular Localization and Function of AT 2 -R in the Kidneys
Ang II has multiple effects on renal function, including modulation of renal blood flow, glomerular filtration rate, tubular epithelial transport, renin release, and cellular growth. 124,125 Autoradiography Studies that simultaneously determined the expression level of AT 1 -R and AT 2 -R are provided. SHR indicates spontaneously hypertensive rats; RHR, renovascular hypertensive rats, and LV, left ventricle.
coupled with competitive binding studies has been used to characterize the distribution of Ang II receptor subtypes in renal tissue. By use of these techniques, the distribution of AT 1 -R and AT 2 -R subtypes within the kidney was shown to be species-dependent. For example, in the rat and rabbit kidneys, Ang II receptors are essentially of the AT 1 -R subtype, 126 -130 whereas both AT 1 -R and AT 2 -R are present within the kidney of the opossum and primates, including humans. 128 -133 The distribution of renal Ang II receptors has been studied most extensively in the rat, where the AT 1 -R binding sites are located predominantly in the glomeruli, the renal tubules, and the renal vasculature. 134, 135 These observations in the rat kidney were further confirmed at mRNA levels using polymerase chain reaction and in situ hybridization 136 -138 ; strong AT 1 -R mRNA signals were detected in the glomerulus, proximal tubules, cortical blood vessels, and collecting ducts. Weaker AT 1 -R mRNA signals were present in the medullary thick ascending limb and medullary collecting ducts. Within the rat glomerulus, AT 1 -R mRNA was localized in mesangial areas, predominantly at the vascular pole and on the terminal portion of the afferent arteriole. In contrast, using mutant mice with a targeted replacement of the AT 1 -R loci by the lacZ, Sugaya et al 139 detected strong lacZ staining in both afferent and efferent arterioles, which agreed with another finding involving the use of polyclonal antisera for rat AT 1 -R. 140 Analyses using Northern blot 7 or in situ hybridization 137 indicated that AT 2 -R mRNA is not present in rat or mouse kidneys. However, autoradiography revealed that in the rabbit, the fibrous sheath around the kidney contains AT 2 -R binding sites 141 and that in the rhesus monkey, AT 2 -R binding sites are present on the juxtaglomerular apparatus and vasculature in the renal cortex. 128 With respect to localization of Ang II receptor subtypes in the human kidney, all studies have been performed on the protein level by autoradiography using [ 125 I]-Ang II as a ligand. 130, 132, 133 Grone et al 132 and Goldfarb et al 133 demonstrated AT 1 -R binding sites predominantly in the glomeruli and tubulointerstitium, whereas AT 2 -R is the major subtype in large cortical blood vessels. In contrast, Sechi et al 130 reported that AT 1 -R is present primarily in both glomeruli and cortical blood vessels and that AT 2 -R protein is not expressed in the human kidney. Analysis of the human renal cortex using in situ hybridization showed strong AT 1 -R mRNA signals localized in interlobular arteries and tubulointerstitial fibrous regions and weaker signals detected in glomeruli and proximal tubules. 142 AT 2 -R mRNA signals were highly localized in interlobular arteries, 142 suggesting a role of AT 2 -R in renal blood flow, which agrees with the diuretic effect of AT 2 -R antagonists. 143 The findings from a study of AT 2 -R null mice indicate AT 2 -R involvement in the formation of the embryonic ureter by the promotion of the mesenchymal cell apoptosis. 144 Lo et al 78 isolated tubular function from hemodynamic action by maintaining a constant renal blood flow and found that the AT 2 -R antagonist PD123319 markedly and rapidly increased diuresis and natriuresis from the rat kidney. Inagami et al 5 also described AT 2 -R knockout mice as not having a diuretic response to PD123319. Siragy et al 74 reported that AT 2 -R stimulates renal production of cGMP in response to Na depletion and that this effect is mediated by NO production. 77 Madrid et al 79 also observed that the activation of the NO/cGMP system by AT 2 -R impaired pressure diuresis. Arima et al 145 reported, with use of microperfused afferent arteriole, that selective activation of AT 2 -R causes endothelium-dependent vasodilation via a cytochrome P-450 pathway, possibly by epoxyeicosatrienoic acids, which suggests that glomerular blood flow is partly regulated by the AT 2 -R in an endothelium-dependent manner.
Pathophysiological Function of the AT 2 -R Identified by Gene-Manipulated Animals
Ichiki et al 9 and Hein et al 10 used targeted deletion to eliminate the gene encoding the AT 2 -R in mice. The resultant AT 2 -R null mice exhibited elevated pressor sensitivity in response to intravenous infusion of Ang II, 9,10 and their basal blood pressure also increased. 9 However, because AT 2 -R expression in the adult vasculature is very low, the underlying mechanism remains unclear. Cardiac targeted overexpression of AT 2 -R in mice was recently generated using an ␣-myosin heavy chain promoter. 54 No obvious morphological changes were observed in the heart, electrocardiograms were normal, and no arrhythmia or conduction block was seen. Infusion of Ang II increased blood pressure and heart rate dose-dependently in wildtype mice, whereas in AT 2 -R transgenic mice, these hemodynamic responses were inhibited markedly without affecting cardiac contractility ( Figure 3 ). This effect was observed at a physiological Ang II concentration range that did not stimulate catecholamine release, suggesting that AT 2 -R decreases the sensitivity of pacemaker cells to Ang II. Tsutsumi et al have used a VSMC-specific ␣-actin promoter to generate transgenic mice that overexpress the AT 2 -R in the vascular system (unpublished data, 1998). Although the basal blood pressure of this transgenic mouse does not differ from that in wild-type mice, the pressor effect by chronic Ang II infusion was abolished, and Ang II-induced contraction of the abdominal artery was significantly increased by an AT 2 -R inhibitor. The increased sensitivity of AT 2 -R knockout mice to the pressor effect of Ang II might be explained partly by lack of AT 2 -R-mediated negative chronotropic action as well as by the reduction of vascular resistance.
Summary and Clinical Applications for AT 1 -R Antagonists
In the near future, several AT 1 -R antagonists will be used for treatment of cardiovascular and renal diseases. However, clinicians should understand the differences in pharmacological effects between AT 1 -R antagonists and ACE inhibitors. Treatment with AT 1 -R antagon causes an increase in plasma Ang II level, which selectively stimulates AT 2 -R 12 ( Figure 4 ). As mentioned above, AT 2 -R stimulation inhibits cardiac fibroblast growth and extracellular matrix formation and exerts a negative chronotropic effect, indicating that AT 2 -R stimulation has a novel cardioprotective effect. Moreover, in human hearts, the distribution ratio of the AT 2 -R is high, and its expression is increased further during heart failure by downregulation of the AT 1 -R. 95, 97, 98, 103, 115 The activation of the kinin/NO/cGMP system mediated through the AT 2 -R is involved partially or dominantly in the cardiovascular and renal effects of the AT 2 -R, raising the possibility that AT 2 -R stimulation has a similar effect to that Mice were anesthetized with pentobarbital, and blood pressure and heart rate were directly measrued with catheters placed in the carotid artery. After 10 minutes of captopril administration (30 mg/kg body weight), Ang II diluted in saline was infused directly into the catheter at different doses in a volume of 10 L. To examine the effect ofexerted by ACE inhibitors such as activation of the kinin/NO system. In fact, Schieffer et al 146 reported that ACE inhibitors and AT 1 -R antagonists are equally effective in preventing ventricular remodeling after myocardial infarction. Very recently, an evaluation of losartan in the elderly compared the effectiveness of the AT 1 -R antagonist losartan and the ACE inhibitor captopril in elderly heart failure patients, and the results showed that losartan was more beneficial than captopril as evidenced by a lower rate of sudden death and hospitalization. 147 These beneficial effects might be partly explained by the potential effect mediated by AT 2 -R. Because blockade of the renin-angiotensin system is essential for the management of patients with heart failure or renal diseases 148 -151 and because AT 1 -R antagonists probably will be used widely for treatment of patients with cardiovascular and renal diseases in the near future, this novel tissue-protective effect of AT 2 -R should be confirmed by clinical studies. 
